Lymphoma Trial, Recruiting (NCT05954910)

Lymphoma Trial, Recruiting NCT05954910 Sponsor: Hoffmann-La Roche Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT05954910 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL)
Group 1: People with DLBCL who are considered too unwell or frail for standard treatment — this includes people aged 80 or older, or younger people whose other health conditions mean their doctor has decided they could not tolerate the standard chemotherapy regimen
Group 2: People with DLBCL who do not fall into the unwell/frail category described above
Group 3: People with DLBCL whose cancer has come back after previous treatment, or whose cancer did not respond to previous treatment

Who may not be able to join:

People who are currently taking part in another clinical trial that involves a medical treatment or intervention, or who plan to join one
People whom the trial doctor considers unsuitable to participate, for any reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Clinical Trials, Hoffmann-La Roche

Phone: 888-662-6728 (U.S. Only)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05954910

Sponsor: Hoffmann-La Roche

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: 888-662-6728 (U.S. Only)

More information: https://clinicaltrials.gov/study/NCT05954910

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a type of blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL)
Group 1: People with DLBCL who are considered too unwell or frail for standard treatment — this includes people aged 80 or older, or younger people whose other health conditions mean their doctor has decided they could not tolerate the standard chemotherapy regimen
Group 2: People with DLBCL who do not fall into the unwell/frail category described above
Group 3: People with DLBCL whose cancer has come back after previous treatment, or whose cancer did not respond to previous treatment

Who may not be able to join:

People who are currently taking part in another clinical trial that involves a medical treatment or intervention, or who plan to join one
People whom the trial doctor considers unsuitable to participate, for any reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hoffmann-La Roche

Registry

ClinicalTrials.gov

Start date

25 August 2023

Est. completion

31 May 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Cohorts 1 and 2: Progression Free Survival at 24 months (PFS24) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma; Cohort 3: PFS Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov